Training Course Blog

What is Cagrilintide?
Cagrilintide (also designated AM833) was developed using structure-activity relationship modeling, with the objective of producing a long-acting amylin analog with retained AMY3R affinity and reduced fibrillation risk.

Several targeted modifications distinguish it from native amylin and pramlintide. bpc-157 10mg

Lipidation: A C20 fatty acid chain attached at the N-terminus supports reversible albumin binding — a well-documented mechanism for extending the serum stability period of peptide hormones. Cagrilintide’s serum stability period has been measured at approximately 159–195 hours in study models, supporting once-weekly compound application intervals.
Proline substitutions (25P/28P/29P): Analogous to rat amylin, these substitutions reduce beta-sheet propensity and inhibit fibril formation, a defining limitation of native amylin.
Salt bridge mutations (14E/17R): These mutations are expected to stabilize the central helix of the peptide through intramolecular salt bridge formation.
C-terminal proline: Added to selectively increase potency at the calcitonin receptor (CTR), completing cagrilintide’s non-selective DACRA receptor profile.
For researchers working in peptide modification and lipidation, the structural vocabulary underlying these modifications is outlined in our peptide glossary.

Receptor Binding Profile: AMY1R, AMY3R, and CTR
Amylin binds to heteromeric receptor complexes formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins 1, 2, or 3 (RAMP1–3), generating three distinct amylin receptor subtypes: AMY1R, AMY2R, and AMY3R.

CTR alone carries higher affinity for calcitonin. Combined with RAMP subunits, it gains substantially greater affinity for amylin.

Cagrilintide is classified as a non-selective agonist across AMYRs and CTR — a DACRA. Receptor pharmacology research published in the Journal of Pharmacology and Experimental Therapeutics characterized cagrilintide’s pharmacological profile across 25 endpoints in cell lines expressing primate, rat, and mouse receptor variants, including HEK293 cells transfected with CTR and AMY3R constructs. Cagrilintide activated AMY1R and CTR with roughly equivalent potency across species in cAMP assays.

This non-selective binding pattern distinguishes it from AMY1R-selective analogs in development and from pramlintide’s more restricted receptor profile.

How Cagrilintide Differs From Salmon Calcitonin in In Vitro Models
Salmon calcitonin (sCT) is the most commonly used reference compound for DACRA research, sharing cagrilintide’s receptor targets.

The key pharmacodynamic distinction lies in receptor residence time. In vitro receptor data show cagrilintide dissociates from all receptor subtypes within 3–6 minutes, while sCT residence times range from 45–60 minutes across the same receptors.

This kinetic difference produces distinct downstream cAMP signaling profiles. Cagrilintide’s cAMP activation in cell assays returns to baseline within a few hours post-application, while sCT maintains a sustained cAMP response. The contrasting body weight outcomes observed between these two compounds in rodent models have been attributed in part to these receptor dynamics.